WeVote
Log In

Bill

Bill

LC 3549

Revise laws relating to prescription drug supply chain and transparency.

2025 Regular Session

Montana bill to increase prescription drug supply chain transparency and oversight dies in drafting stage before legislative consideration.

(LC) Draft Died in Process
#insurance
0
WeVote Research Nonpartisan
Bill Summary · LC 3549

Legislative bill overview

LC 3549 proposes revisions to Montana's laws governing the prescription drug supply chain and transparency requirements. The bill aims to increase oversight and information disclosure related to how medications move from manufacturers through wholesalers and pharmacies to consumers. Specific provisions are not available in the public record, as the draft died in the legislative process before advancement.

Why is this important

Prescription drug supply chain transparency directly affects medication costs, drug availability, and patient safety. Increased transparency can help identify price manipulation, counterfeit drugs, and supply disruptions that impact Montana residents' access to affordable medications. These issues have generated national attention as state legislatures seek ways to combat rising drug prices and ensure medication integrity.

Potential points of contention

  • Compliance costs: Requiring supply chain tracking and reporting could impose significant burdens on pharmacies, wholesalers, and smaller businesses, potentially increasing operational expenses that may be passed to consumers
  • Manufacturer/industry pushback: Pharmaceutical companies and distributors may resist transparency mandates as competitive threats or privacy concerns regarding proprietary pricing and distribution data
  • Implementation clarity: Without seeing the final draft language, there's uncertainty about whether requirements would be feasible, how enforcement would work, and which entities would bear primary responsibility

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.